Breast Magnetic Resonance Imaging (MRI)

Sharma, Uma; Sharma, Raju; Jagannathan, N. R.

doi:10.1002/9780470034590.emrstm0045.pub2

Cited by 7 publications

(6 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The commonly used methods for diagnosis of breast cancer are physical examination, radiological evaluation using ultrasonography, and mammography followed by histopathological evaluation, which is the gold standard. The advantage of MRI compared with ultrasonography and mammography is that it is helpful to differentiate malignant from benign breast lesions with the use of dynamic contrast-enhanced MRI (DCEMRI) in addition to detecting multifocal and multicentric disease (4,5). However, most studies reported poor specificity of DCEMRI ranging from 20 to 100% (6).…”

mentioning

confidence: 99%

Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Sah

Sharma

Parshad

et al. 2011

Magnetic Resonance in Med

Self Cite

View full text Add to dashboard Cite

The association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) status of breast cancer patients with total choline (tCho) concentration and tumor volume was investigated using in vivo proton magnetic resonance spectroscopy and MRI at 1.5 T. Values for tCho concentration were determined in 120 locally advanced breast cancer patients (stages IIB, IIIA, IIIB, and IIIC), 31 early breast cancer patients (stage IIA), 38 patients with benign lesions, and 37 controls. Significantly higher tCho concentration and lower tumor volume were observed in early breast cancer patients compared to locally advanced breast cancer patients (P<0.05). tCho concentration and tumor volume did not correlate with age and menstruation. tCho cutoff values were obtained for the differentiation of malignant from benign breast tissues (2.54 mmol/kg); malignant versus normal (1.45 mmol/kg) and benign versus normal tissues (0.82 mmol/kg). Estrogen receptor negative patients showed significantly larger tumor volumes, indicating higher angiogenesis with aggressive tumor behavior. Nontriple negative and triple positive patients had a significantly higher tCho concentration compared to triple negative patients (P<0.05), indicating complex molecular mechanism of cell proliferation and the molecular heterogeneity of breast lesions. The results indicate the potential use of integration of breast 1H magnetic resonance spectroscopy in diagnostic workup.

show abstract

mentioning

confidence: 99%

Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Sah

Sharma

Parshad

et al. 2011

Magnetic Resonance in Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…DCEMRI is routinely used for discriminating between malignant and benign breast diseases (Figure ). It shows good sensitivity but with variable specificity in the range 37–97% .…”

Section: Mri‐related Methods In the Study Of Breast Cancer Metabolismmentioning

confidence: 99%

“…A, Subtracted gadolinium‐enhanced T 1 ‐weighted axial image from an LABC patient showing homogenous enhancement of the signal; B, the signal intensity‐time curve from the circular ROI showing early peak enhancement with rapid washout strongly suggestive of malignancy. C, Subtracted axial gadolinium‐enhanced T 1 ‐weighted axial image of a patient with a benign breast lesion that shows homogenous enhancement; D, the signal intensity‐time curve obtained from the circular ROI showing progressive enhancement suggestive of a benign lesion (reprinted from Reference with permission from John Wiley & Sons, Inc.)…”

Section: Mri‐related Methods In the Study Of Breast Cancer Metabolismmentioning

confidence: 99%

Application of in vivo MR methods in the study of breast cancer metabolism

Jagannathan

2018

NMR in Biomedicine

Self Cite

View full text Add to dashboard Cite

In the last two decades, various in vivo MR methodologies have been evaluated for their potential in the study of cancer metabolism. During malignant transformation, metabolic alterations occur, leading to morphological and functional changes. Among various MR methods, in vivo MRS has been extensively used in breast cancer to study the metabolism of cells, tissues or whole organs. It provides biochemical information at the metabolite level. Altered choline, phospholipid and energy metabolism has been documented using proton ( 1 H), phosphorus ( 31 P) and carbon ( 13 C) isotopes. Increased levels of choline-containing compounds, phosphomonoesters and phosphodiesters in breast cancer, which are indicative of altered choline and phospholipid metabolism, have been reported using in vivo, in vitro and ex vivo NMR studies. These changes are reversed on successful therapy, which depends on the treatment regimen given.Monitoring the various tumor intermediary metabolic pathways using nuclear spin hyperpolarization of 13 C-labeled substrates by dynamic nuclear polarization has also been recently reported. Furthermore, the utility of various methods such as diffusion, dynamic contrast and perfusion MRI have also been evaluated to study breast tumor metabolism. Parameters such as tumor volume, apparent diffusion coefficient, volume transfer coefficient and extracellular volume ratio are estimated. These parameters provide information on the changes in tumor microstructure, microenvironment, abnormal vasculature, permeability and grade of the tumor. Such changes seen during cancer progression are due to alterations in the tumor metabolism, leading to changes in cell architecture. Due to architectural changes, the tissue mechanical properties are altered; this can be studied using magnetic resonance elastography, which measures the elastic properties of tissues. Moreover, these structural MRI methods can be used to investigate the effect of therapy-induced changes in tumor characteristics. This review discusses the potential of various in vivo MR methodologies in the study of breast cancer metabolism.

show abstract

“…Mammography and sonography are frequently used for the evaluation of breast malignancy; however, they are not accurate in differentiating between chemotherapy‐induced fibrosis and residual tumor 3, 11–13. Breast MRI is useful for clinical staging and also for the measurement of residual disease by determining the size of the tumor both prior to and after therapy 14–16. Several studies have reported that dynamic contrast‐enhanced MRI is more effective than mammography, sonography or clinical examination for the estimation of residual disease following chemotherapy 17–20.…”

Section: Introductionmentioning

confidence: 99%

In vivo¹H MRS in the assessment of the therapeutic response of breast cancer patients

Sharma

Baek

et al. 2011

NMR in Biomedicine

Self Cite

View full text Add to dashboard Cite

MRI and in vivo MRS have rapidly evolved as sensitive tools for diagnosis and therapeutic monitoring in cancer research. In vivo MRS provides information on tumor metabolism, which is clinically valuable in the diagnosis and assessment of tumor response to therapy for the management of women with breast diseases. Several centers complement breast MRI studies with 1H MRS to improve the specificity of diagnosis. Malignant breast tissues show elevated water-to-fat ratio and choline-containing compounds (total choline, tCho), and any effect of therapy on tissue viability or metabolism will be manifested as changes in these levels. Sequential 1H MRS studies have shown significantly reduced tCho levels during the course of therapy in patients who were responders. However, there are challenges in using in vivo MRS because of the relatively low sensitivity in detecting the tCho resonance with decreased lesion size or significant reduction in the tumor volume during therapy. MRS is also technically challenging because of the low signal-to-noise ratio and heterogeneous distribution of fat and glandular tissues in the breast. MRS is best utilized for the diagnosis of focal masses, most commonly seen in patients with ductal-type neoplasms; however, it has limitations in detecting nonfocal masses, such as the linear pattern of tumors seen in invasive lobular carcinoma. Further work is required to assess the clinical utility of quantitative MRS, with the goal of automation, which will reduce the subjectivity currently inherent in both qualitative and semi-quantitative MRS.

show abstract

Breast Magnetic Resonance Imaging (MRI)

Cited by 7 publications

References 114 publications

Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Application of in vivo MR methods in the study of breast cancer metabolism

In vivo¹H MRS in the assessment of the therapeutic response of breast cancer patients

Contact Info

Product

Resources

About

Breast Magnetic Resonance Imaging (MRI)

Cited by 7 publications

References 114 publications

Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study

Application of in vivo MR methods in the study of breast cancer metabolism

In vivo1H MRS in the assessment of the therapeutic response of breast cancer patients

Contact Info

Product

Resources

About

In vivo¹H MRS in the assessment of the therapeutic response of breast cancer patients